ERFSF:OTO-Eurofins Scientific Nante (USD)

COMMON STOCK | Diagnostics & Research | OTC Pink

Last Closing

USD 59.96

Change

0.00 (0.00)%

Market Cap

USD 7.27B

Volume

1.85K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Eurofins Scientific SE is engaged providing food, environment and pharmaceutical products testing. It also provides agroscience, genomics, discovery pharmacology and central laboratory services; and also specialty clinical diagnostic testing.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
LZAGF Lonza Group Ltd

N/A

USD 41.97B
LZAGY Lonza Group AG

N/A

USD 41.89B
WUXIF WuXi AppTec Co. Ltd

N/A

USD 17.70B
BMXMF bioMérieux S.A

N/A

USD 12.65B
SKHCF Sonic Healthcare Limited

N/A

USD 8.77B
SKHHY Sonic Healthcare Ltd ADR

N/A

USD 8.63B
HNGZY Hangzhou Tigermed Consulting C..

N/A

USD 5.92B
DSRLF DiaSorin S.p.A

N/A

USD 5.73B
VIMGF Vimian Group AB (publ)

N/A

USD 1.45B
MRCHF H.U. Group Holdings Inc

N/A

USD 0.82B

ETFs Containing ERFSF

MXU:CA Mackenzie Maximum Diversi.. 0.00 % 0.62 %

N/A

CAD 0.05B
IDLB 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.76% 47% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.76% 47% F 38% F
Trailing 12 Months  
Capital Gain -16.30% 67% D+ 46% F
Dividend Return 1.52% 70% C- 19% F
Total Return -14.78% 67% D+ 45% F
Trailing 5 Years  
Capital Gain 1,245.33% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,245.33% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 398.53% 93% A 93% A
Dividend Return 400.35% 93% A 92% A
Total Return 1.82% 57% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 708.70% 13% F 12% F
Risk Adjusted Return 56.49% 98% N/A 90% A-
Market Capitalization 7.27B 94% A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.